Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies I
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
IFNγ neutralization by the clinically approved monoclonal antibody emapalumab mitigates severe toxicity related to CAR-T therapy Emapalumab does not impair CAR.CD19 T-cell activation signaling Un-transduced (NT) and CAR.CD19 T-cells were activated with 0.5 μg/ml recombinant human CD19 Fc Chimera Protein for 16 hours before the analysis of the gene signature in presence or absence of Emapalumab
创建时间：
2023-08-14
